Antivr is a privately held biotech company with a broad portfolio of anti-viral human monoclonal antibody (mAb) product candidates that is complemented by a human mAb discovery and manufacturing platform technology. Antivr’s mission is to leverage the unique advantages of mAbs to address the unmet medical needs in high-risk populations where vaccines don’t work or do not work well. Our pipeline comprised of mAbs directed against seasonal and pandemic viruses.

Website coming soon……